6-K
Radiopharm Theranostics Ltd (RADX)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the Month of November 2025
Commission File Number: 001-41621
RADIOPHARM THERANOSTICS LIMITED
(Name of Registrant)
Level 3, 62 Lygon Street, Carlton South,Victoria, 3053, Australia
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ☐ No ☒
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-
RADIOPHARM THERANOSTICS LIMITED
EXPLANATORY NOTE
Radiopharm Theranostics Limited (the “Company”) published two announcements (the “Public Notice”) to the Australian Securities Exchange on November 19, 2025 titled:
| “Initial Director’s Interest Notice” |
|---|
| “Life Sciences Leader Bruce Goodwin Appointed to Board” |
A copy of the Public Notice is attached as an exhibit to this report on Form 6-K.
This report on Form 6-K (including the exhibit hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
1
EXHIBITS
| Exhibit <br><br>Number | Description |
|---|---|
| 99.1 | Initial Director’s Interest Notice |
| 99.2 | Life Sciences Leader Bruce Goodwin Appointed to Board |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| RADIOPHARM THERANOSTICS LIMITED | ||
|---|---|---|
| Date: November 19, 2025 | By: | /s/ Phillip Hains |
| Phillip Hains | ||
| Company Secretary |
3
Exhibit 99.1
Appendix 3X
Initial Director’s Interest Notice
Rule 3.19A.1
Appendix 3X
Initial Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.
Introduced 30/9/2001.
| Name of entity: Radiopharm Theranostics Limited (ASX: RAD) |
|---|
| ABN: 57 647 877 889 |
We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.
| Name of Director | Bruce Goodwin |
|---|---|
| Date of appointment | 19 November 2025 |
Part 1 - Director’s relevantinterests in securities of which the director is the registered holder
In the case of a trust, thisincludes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.
| Number & class of securities<br><br> <br><br><br> <br><br><br> <br>Nil. |
|---|
| + See chapter 19 for defined terms. |
| --- |
| 11/3/2002 |
| Appendix 3X Page 1 |
Appendix 3X
Initial Director’s Interest Notice
Part 2 – Director’s relevant interests in securities of which the director is not the registered holder
In the caseof a trust, this includes interests in the trust made available by the responsible entity of the trust
| Name of holder & nature of interest<br><br> <br>Note: Provide details of the<br> circumstances giving rise to the relevant interest.<br><br> <br><br><br> <br><br><br> <br><br><br> <br><br><br> <br><br><br> <br><br><br> <br><br><br> <br><br><br> <br>**** | Number & class of Securities<br><br> <br><br><br> <br><br><br> <br>Nil. |
|---|
Part 3 –Director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.
| Detail of contract | N/A |
|---|---|
| Nature of interest **** **** | N/A |
| Name of registered holder(if issued securities) | N/A |
| No. and class of securitiesto which interest relates | N/A |
| + See chapter 19 for defined terms. | |
| --- | --- |
| Appendix 3X Page 2 | 11/3/2002 |
Exhibit99.2
| ASX ANNOUNCEMENT 19 NOVEMBER 2025 |
|---|
LIFE SCIENCES LEADER BRUCE GOODWINAPPOINTED
NON-EXECUTIVE DIRECTOR
Sydney, Australia – 19 November 2025 – Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce the appointment of Mr Bruce Goodwin as a Non-Executive Director, effective 19 November 2025.
Mr Goodwin is a highly respected leader in the life sciences sector, bringing over four decades of experience across global healthcare and biopharmaceutical industries. He currently serves as a Non-Executive Director across six organisations operating within the healthcare sector, where he provides strategic guidance and governance expertise.
Mr Goodwin’s career includes more than three decades with the Janssen Pharmaceutical Companies of Johnson & Johnson, during which he held senior leadership roles across multiple countries and regions. His tenure was marked by a strong record of driving organisational growth, fostering innovation, and leading high-performing teams in complex, multinational environments.
Mr Goodwin has demonstrated a deep commitment to advancing the life sciences industry. He has served on industry peak body boards in Australia and Japan, contributing to policy development, regulatory dialogue, and cross-sector collaboration. He is also regarded for his strategic acumen, global perspective, and passion for improving health outcomes through innovation, leadership, and effective governance.
In conjunction with this appointment, Radiopharm advises that Mr Phillip Hains and Dr Leila Alland will retire from the Board at the 2025 Annual General Meeting this month. Mr Hains will continue in his current roles as Chief Financial Officer and Company Secretary following his retirement from the Board.
Radiopharm Executive Chairman Paul Hopper said:
“We are delighted to welcome Bruce to the Radiopharm Board.His exceptional leadership experience, particularly his long tenure with Johnson & Johnson and deep understanding of the biopharmaceuticallandscape, will be invaluable as we continue to advance our pipeline and strengthen our global profile.
On behalf of the Board, I would also like to thank Phillip and Leilafor their contributions to Radiopharm’s growth and governance since listing. We look forward to continuing to work closely withPhillip in his executive capacities and with Leila as a consultant to the Medical Team of Radiopharm.”
Radiopharm TheranosticsLimited
Suite 1, Level 3, 62Lygon Street, Carlton South VIC 3053 Australia
ABN: 57 647 877 889
| ASX ANNOUNCEMENT 19 NOVEMBER 2025 |
|---|
About Radiopharm Theranostics
Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. Radiopharm is listed on ASX (RAD) and on NASDAQ (RADX). The company has a pipeline of distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase 2 and three Phase 1 trials in a variety of solid tumor cancers including lung, breast, and brain metastases. Learn more at radiopharmtheranostics.com.
Authorised on behalf of the Radiopharm Theranostics Board of Directorsby Executive Chairman Paul Hopper.
For more information:
Investors:
Riccardo Canevari
CEO & Managing Director
P: +1 862 309 0293
E: rc@radiopharmtheranostics.com
Anne Marie Fields
Precision AQ
(Formerly Stern IR)
E: annemarie.fields@precisionaq.com
Media:
Matt Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au
Follow Radiopharm Theranostics:
Website – https://radiopharmtheranostics.com/
Twitter – https://twitter.com/TeamRadiopharm
Linked In – https://www.linkedin.com/company/radiopharm-theranostics/
InvestorHub – https://investorhub.radiopharmtheranostics.com/
Radiopharm TheranosticsLimited
Suite 1, Level 3, 62Lygon Street, Carlton South VIC 3053 Australia
ABN: 57 647 877 889